Replies to post #141226 on Biotech Values

[DewDiligence]

the [Squalamine] eyedrop will be given twice a day.

Regardless of the route of administration and the dosing frequency, the fundamental problem with Squalamine is that it’s a relatively weak VEGF inhibitor. It was taken from nature “as is,” and was never subjected to the medicinal-chemistry optimizations that are typically done on a small-molecule drug.

[DewDiligence]

If you’re attending ARVO, you can see OHRP’s poster on Squalamine eye drops:

http://finance.yahoo.com/news/ohr-pharmaceutical-present-arvo-annual-123000769.html

Abstract title: “A Novel Eye Drop Formulation of Squalamine For Exudative AMD: Evaluation Of Ocular Distribution And Ocular Safety In Rabbits”

Recap: Ten years after this drug was first tested in human eyes, we have a distribution and safety study in rabbits!

I’m willing to bet that this program won’t work for the reason mentioned in #msg-75138549.